RNA Manufacturing Articles

31. Bridging The Manufacturing Chemistries Between Drug Research And Development For Morpholino Oligos 4/29/2026

    Standardizing Morpholino chemistry could streamline development and FDA pathways, improving consistency, scalability, and delivery performance across antisense therapeutics.

32. From Supporting Component to Strategic Driver: The Evolving Role of gRNA in CRISPR Therapeutics 4/21/2026

    Guide RNA is evolving from a simple targeting reagent into a complex, engineered molecule shaped by expanding CRISPR modalities, increasing length and modification demands, and tighter integration with manufacturability, analytical control, and regulatory expectations.

33. A Novel Co-Tethered Transcription Platform For High-Yield, High-Purity mRNA Synthesis 4/15/2026

    Co-tethered transcription boosts mRNA yield and purity by organizing transcription machinery, reducing dsRNA impurities, and streamlining production for scalable RNA therapeutics.

34. A New Approach To RNA Synthesis And Purification: Rethinking A Persistent Bottleneck 4/14/2026

    Photocleavable supports enable light-triggered RNA release, reducing reliance on chromatography and streamlining synthesis, scalability, and purity for complex RNA therapeutics.

35. Oligos, mRNA, Or Gene Editing: Where Should You Bet? 4/13/2026

    Investing in RNA and gene editing requires balancing risk, timing, and scale — understanding how oligos, mRNA, and CRISPR each drive value across a converging biotech landscape.

36. Beyond The Gold Standard(s): Modernizing Oligonucleotide Synthesis 4/13/2026

    A few weeks ago, I had the chance to sit down with OPT Congress speaker Phil Baran, Richard Lerner Chair Professor, Department of Chemistry, Scripps Research. Baran was slated to (and did) present a keynote on the innovations shaping the next generation of oligo synthesis. Here, I share the biggest takeaways I had from our conversation, touching on how he sees the science of oligo chemistry and manufacturing advancing in the near and far future. 

37. The RNA Ties That Bind: 3 Takeaways From The OPT Congress 4/1/2026

    Here, I unpack three takeaways I had from the OPT Congress, each of which I’d argue are indicative of the interconnectedness across the genetic medicines field.

38. Rethinking ATMP Assurance When Sterility Timelines, Reality Misalign 3/27/2026

    The compendial 14-day sterility testing window exposes product and patient to numerous risks, but settling on a rapid alternative also presents its own set of challenges.

39. The Potency Chains Of Events For mRNA/LNP Therapeutics 3/25/2026

    Potency in mRNA/LNP therapies depends on two chains: manufacturing/cold chain integrity and complex in vivo delivery. Breakdowns at any step — from stability to translation — can limit efficacy and safety.

40. How Informal FDA Feedback Is Quietly Driving RNA Capital Allocation 3/19/2026

    Subtle FDA signals — especially in pre-IND talks — are quietly shaping RNA investment. Early regulatory feedback on CMC and comparability now drives how investors assess risk and allocate capital.